-
Population pharmacokinetic and pharmacodynamic modelling to improve tuberculosis treatment
-
Population pharmacokinetic modelling to address the gaps in knowledge of commonly used HIV and TB drugs in children
-
Population pharmacokinetic modelling for dose optimization of esomeprazole to treat early-onset preeclampsia
-
Pharmacogenomics and pharmacokinetics of antiretroviral drugs and their associations with metabolic complications in HIV-infected Black South Africans
-
Characterizing population pharmacokinetic/pharmacodynamic relationships in pulmonary tuberculosis infected adults using nonlinear mixed effects modelling
-
A pharmacokinetic and antimalarial efficacy evaluation of pyridodibemequines and their metabolites
-
Pharmacogenomics and pharmacokinetics of dolutegravir and tenofovir in Southern Africans living with HIV
-
The antiplasmodial, toxicity and pharmacokinetic properties of synthetic derivatives of the natural product Curcumin
-
The pharmacokinetics of lopinavir in HIV-infected adults receiving rifampicin with adjusted doses of lopinavir
-
Pharmacokinetic profile of amodiaquine and its active metabolite desethylamodiaquine in Ghanaian patients with uncomplicated Falciparum malaria
-
Pharmacokinetics, pharmacogenetics and optimisation of treatment with non-nucleoside reverse transcriptase inhibitors in HIV-infected African children
-
Clinical, pharmacokinetic, and genetic determinants of change in serum creatinine among Southern Africans on dolutegravir based antiretroviral therapy
-
Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis
-
Pharmacometric modelling to inform and improve TB and HIV treatment: Focus on drug-drug interactions and neglected populations
-
Variability in the pharmacokinetics of rifapentine in South African tuberculosis patients : a classical and population approach
-
The Plasma, Whole Blood and Intracellular Concentrations of Antiretroviral Agents in South African Children Receiving Combination Antiretroviral Therapy with and without Concomitant Antitubercular Treatment
-
Antimalarial activity and pharmacokinetic properties of new chemical entities
-
A critical appraisal of the clinical pharmacokinetics of isoniazid
-
Determinants and consequences of the pharmacokinetics of rifampicin, isoniazid, pyrazinamide and ethambutol in a cohort of tuberculosis patients
-
In vitro assessment of some traditional medications used in South Africa for pharmacokinetics drug interaction potential
-
Pharmacometrics of dolutegravir and tenofovir: a quantitative approach to characterise drug-drug interactions, pharmacogenetics and optimise treatment
-
The role of the pharmacokinetics, host folate levels and parasite mutations in the in vivo efficacy of pyrimethamine-sulfadoxine against Plasmodium falciparum
-
The clinical role of therapeutic drug monitoring of antiretrovirals : a Cochrane systematic review
-
Determination of total, unbound, and intracellular concentrations of the antiretroviral drugs Efavirenz, Lopinavir, and Ritonavir
